ERBB2 and breast carcinoma: Inhibition of uPAR expression along with the expression of uPA, human epidermal growth factor receptor-2 (HER-2), or IGF1R or in combination with trastuzumab further inhibits the invasion and migration of different breast cancer cell lines [66–68].